医药流通规模位列行业第三。2025 上半年，公司医药流通收入达到1,100 亿元，规模位列行业第三，仅 次于国药控股和上海医药。1）分销：持续拓展创新产品，商业模式逐步从传统分销转换至分销加深度 营销双轮驱动。2025 年上半年，公司分销业务收入达到1,083 亿元，其中医疗器械业务收入达到180 亿 元，同比增长8%。2）零售：持续加强DTP 等专业药房建设，以及打造院外新零售体系，建立差异化竞 争优势。2025 年上半年，公司零售业务收入达到55 亿元，同比增长11%。 首次覆盖给予买入评级。我们预计2025-2027 年公司归属普通股东净利润分别为34.9/37.6/40.5 亿元，同 比增长4.0%/7.9%/7.7%。根据公司所属板块及主营业务，我们选取国药控股、上海医药等聚焦医药流通 且具备一定知名度的企业作为可比公司。我们给予公司2026 年8.7 倍PE，对应市值为353 亿港元，目前 市值285 亿港元，对应24%的上涨空间，首次覆盖给予买入评级。 风险提示：市场竞争加剧；集采降价压力；并购整合低于预期。 国内第一大OTC 制造商，品牌势能集聚。公司制药业务以健康消费品（CHC）为主。202 ...

Core Insights - The eighth "Belt and Road" Traditional Chinese Medicine (TCM) Development Forum and the third OTC Brand Conference were held in Hangzhou, focusing on high-quality development in the context of the Belt and Road Initiative [2] - The forum aimed to create a high-quality platform for international exchange in TCM and OTC brands, emphasizing the integration of government, industry, academia, research, and application [2] - The OTC market in China is projected to exceed 300 billion yuan by 2024, with a compound annual growth rate of 4.6% from 2018 to 2024 [3] Group 1 - The forum gathered representatives from various countries, international organizations, regulatory bodies, industry leaders, and experts to discuss TCM innovation and the upgrading of OTC brands [2] - The president of the China Non-Prescription Drug Association highlighted the importance of TCM and the OTC industry in promoting high-quality development and public health [2] - Bayer's general manager emphasized the need for patient-centered policies that enhance product accessibility and understanding [2] Group 2 - The demand for TCM has shifted from "treating illness" to "daily health management," with consumers increasingly focusing on preventive care and wellness [3] - There are three emerging opportunities in the TCM industry: increased attention to niche categories, a rise in service-oriented consumption, and the integration of online and offline channels for consumer engagement [3] - The association aims to promote the healthy development of the OTC industry and enhance the global presence of Chinese OTC and TCM brands [3]